Arecor Therapeutics PLC Cash Flow Conversion Efficiency
Arecor Therapeutics PLC cash flow conversion efficiency. Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has a cash flow conversion efficiency ratio of -0.178x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.15 Million ≈ $-139.56 USD) by net assets (GBX6.45 Million ≈ $785.27 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Arecor Therapeutics PLC (2018–2025)
Cash flow conversion efficiency of Arecor Therapeutics PLC from 2018 to 2025. This chart illustrates how Arecor Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Arecor Therapeutics PLC stock price for real-time trading data and today's change.
Arecor Therapeutics PLC Cash Flow Conversion Ratio Explained
Arecor Therapeutics PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Arecor Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arecor Therapeutics PLC ranked by their cash flow conversion efficiency. Also see Arecor Therapeutics PLC stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BLUERUSH Media Group Corp
V:BTV
|
-0.015x |
|
KOYJ Co. Ltd
KQ:121850
|
-1.361x |
|
Palace Capital PLC
LSE:PCA
|
0.028x |
|
Lidds AB
ST:LIDDS
|
-0.413x |
|
Imobiliária Construtora Grão Pará S.A.
LS:GPA
|
0.000x |
|
Sangrix Inc.
NASDAQ:SGRX
|
1.157x |
|
SY PUBLIC UTIL -H- (SH3.SG)
STU:SH3
|
-0.751x |
|
Empresa Distribuidora Electrica Regional SA
BA:EMDE
|
0.011x |
Annual Cash Flow Conversion Efficiency for Arecor Therapeutics PLC (2018–2025)
The table below shows the annual cash flow conversion efficiency of Arecor Therapeutics PLC from 2018 to 2025. Review AREC FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX6.45 Million ≈ $785.27 |
GBX-2.29 Million ≈ $-278.63 |
-0.355x | +79.27% |
| 2024-12-31 | GBX5.35 Million ≈ $650.82 |
GBX-9.15 Million ≈ $-1.11K |
-1.712x | -179.16% |
| 2023-12-31 | GBX9.53 Million ≈ $1.16K |
GBX-5.84 Million ≈ $-710.68 |
-0.613x | +0.73% |
| 2022-12-31 | GBX17.45 Million ≈ $2.12K |
GBX-10.78 Million ≈ $-1.31K |
-0.618x | -110.20% |
| 2021-12-31 | GBX18.55 Million ≈ $2.26K |
GBX-5.45 Million ≈ $-663.11 |
-0.294x | +87.75% |
| 2020-12-31 | GBX773.79K ≈ $94.15 |
GBX-1.86 Million ≈ $-225.90 |
-2.399x | -1577.65% |
| 2019-12-31 | GBX3.21 Million ≈ $390.31 |
GBX-458.80K ≈ $-55.82 |
-0.143x | +75.93% |
| 2019-05-31 | GBX4.22 Million ≈ $512.95 |
GBX-2.50 Million ≈ $-304.76 |
-0.594x | +19.14% |
| 2018-05-31 | GBX670.33K ≈ $81.56 |
GBX-492.57K ≈ $-59.93 |
-0.735x | -- |
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a no… Read more